Chemed (NYSE: CHE) is expected to report Q3 earnings on Oct. 29. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Chemed's revenues will grow 5.5% and EPS will grow 20.5%.

The average estimate for revenue is $360.2 million. On the bottom line, the average EPS estimate is $1.35.

Revenue details
 Last quarter, Chemed reported revenue of $354.2 million. GAAP reported sales were 6.2% higher than the prior-year quarter's $333.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $1.26. GAAP EPS of $1.10 for Q2 were 17% higher than the prior-year quarter's $0.94 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 27.3%, 80 basis points worse than the prior-year quarter. Operating margin was 11.2%, 40 basis points better than the prior-year quarter. Net margin was 6.0%, 10 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $1.44 billion. The average EPS estimate is $5.37.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 93 members out of 107 rating the stock outperform, and 14 members rating it underperform. Among 36 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 32 give Chemed a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Chemed is outperform, with an average price target of $68.25.